David M. Knott’s Aimmune Therapeutics AIMT Stock Holding History

David M. Knott’s Portfolio AIMT Stock Details AIMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-55,990	Closed	-$1.87M	–	126
2019 Q4	$1.87M	Hold	55,990	–	–	0.76%	25
2019 Q3	$1.17M	Sell	55,990 -1,466	-3%	-$29.9K	0.49%	36
2019 Q2	$1.2M	Buy	57,456 +2,400	+4%	+$49.4K	0.5%	35
2019 Q1	$1.23M	Buy	55,056 +2,199	+4%	+$51.8K	0.49%	41
2018 Q4	$1.26M	Buy	52,857 +8,705	+20%	+$225K	0.59%	34
2018 Q3	$1.2M	Buy	44,152 +3,372	+8%	+$95.4K	0.39%	39
2018 Q2	$1.1M	Buy	40,780 +11,000	+37%	+$337K	0.41%	39
2018 Q1	$948K	Buy	29,780 +21,749	+271%	+$765K	0.39%	36
2017 Q4	$304K	Buy	8,031 +6,031	+302%	+$195K	0.12%	73
2017 Q3	$50K	Buy	+2,000	New	+$43.1K	0.02%	92

Other funds holding AIMT

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

David M. Knott's AIMT Position: Q1 2020 in Review

David M. Knott sold out of Aimmune Therapeutics (AIMT) in Q1 2020, closing a stake of 55,990 shares — an estimated $1.87M sold.

David M. Knott first reported a position in AIMT in Q3 2017 and held it in 10 quarters. The position peaked at $1.87M in Q4 2019. 161 funds tracked by Wall St. Rank hold AIMT as of Q1 2020.

David M. Knott reported no remaining Aimmune Therapeutics position as of Q1 2020 after selling out during the quarter.
David M. Knott sold 55,990 Aimmune Therapeutics shares in Q1 2020, an estimated $1.87M.
David M. Knott first reported a position in Aimmune Therapeutics in Q3 2017 and held it in 10 quarters.
David M. Knott's Aimmune Therapeutics position peaked at $1.87M in Q4 2019.
161 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q1 2020.

Based on David M. Knott's 13F filing for Q1 2020, filed 13 May 2020.